Lundbeck’s investigational oral orexin 2 receptor agonist gains Fast Track status, aiming to address underlying pathophysiology in patients with narcolepsy.

Cancer progression within 36 months of combination therapy identified patients with overall survival of less than 2 years.

One in about 7300 individuals in the general population have PMS, a rare genetic condition that causes medical, intellectual, and behavioral challenges.

Delaying JAK inhibitor initiation yielded higher early antibody responses; earlier initiation linked to earlier improvement in arthritis.

For patients aged 4 to 66 years with acquired hypothalamic obesity, setmelanotide leads to significantly greater reductions ...

Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.

TG-C is a novel, off-the-shelf cell and gene therapy designed to slow OA progression and provide a non-surgical alternative to standard of care therapies.

The FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for pretreated, advanced squamous cell carcinoma of the anal canal based on phase 1/2 GOBLET trial ...

In the CALIBRATE trial, 76% of encaleret-treated patients normalized both blood and urine calcium at week 24 vs 4% on standard of care, while 91% achieved intact PTH restoration.

Benefits include improvements for resilience and prosocial behavior, but not symptoms of anxiety or depression.

Cherry angiomas (CAs), also known as Campbell de Morgan spots, are common, benign, well-demarcated cutaneous vascular ...